Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.34 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 2/20 | 0.31 |
| ▸ | FNTB | P49356 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL10973447 | 0.80 | FFAR3 (0.44) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL2158345 | 0.77 | — | — | |
| SCHEMBL14094993 | 0.77 | FFAR3 (0.36) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL1127391 | 0.77 | TDP1 (0.36) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL1127385 | 0.77 | TDP1 (0.36) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL42601 | 0.76 | FFAR3 (0.53) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL101165 | 0.76 | FFAR3 (0.53) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL42603 | 0.76 | FFAR3 (0.53) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL17706738 | 0.76 | FFAR3 (0.47) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL17706737 | 0.76 | FFAR3 (0.47) | FFAR3GRIK1GRIA4GRIK3GRIK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| EP-1631570-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Abbott Laboratories (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004083207-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1340747-A1 | Process for the preparation of 2-halogene-alkyl nicotinic acid alkyl-esters | BAYER AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | FFAR3 3722/4885GRIK1 3104/4885GRIA4 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.